Accessibility Statement Skip Navigation
  • Resources
  • Data Privacy
  • Contact Us
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • All Multimedia

        • All Multimedia
        • All Photos
        • All Videos
    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Accessories
        • Computer Hardware
        • Computer Networks
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High-Tech Security
        • Internet Technology
        • Nanotechnology
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art, Culture & Design
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Projections or Forecasts
        • Financing Agreements
        • Insurance
        • Joint Ventures
        • Mutual Funds
        • Offerings
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing/marketing agreements
        • New Products & Services
        • Obituary
        • Outsourcing Businesses
        • Overseas Real Estate (Non-US)
        • Personnel Announcements
        • Residential Real Estate
        • Small-Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Accessories
        • Computer Electronics
        • Computer Hardware
        • Computer Networks
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Design Automation
        • Financial Technology
        • Mobile Devices/Apps
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Natural Gas Utilities
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Computer Accessories
        • Computer Networks
        • Mobile Devices/Apps
        • Telecommunications
        • Telecommunications Carriers & Services
        • Telecommunications Equipment
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wine & Spirits
        • Beverages
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art, Culture & Design
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infectious Disease Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental Products & Services
        • European Government
        • Natural Disasters
        • Not-for-Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Children-related news
        • Disabled Persons
        • Diversity, Equity & Inclusion
        • Hispanic-oriented news
        • LGBTQ+
        • Religion
        • Senior Citizens
        • Veterans
        • Women-Related news
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Request a Demo
    • Partnerships
    • Media Inquiries
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring Home
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us


    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • News Releases
      • Send a Release
      • Data Privacy
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • News Releases
      • Send a Release
      • Data Privacy
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • News Releases
      • Send a Release
      • Data Privacy
      • General Inquiries
      • Request a Demo
      • Partnerships
      • Media Inquiries
      • Editorial Bureaus
      • News Releases
      • Send a Release
      • Data Privacy
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • All Multimedia
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Prenetics Announces First Quarter 2023 Financial Results


      News provided by

      Prenetics

      05 Jun, 2023, 19:20 CST

      Share this article

      Share this article


      HONG KONG, June 5, 2023 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics and precision oncology company, today announced financial results for the first quarter ended March 31, 2023, along with recent business updates.

      First Quarter 2023 Financial Highlights

      • Revenue of US$17.7 million
      • Adjusted EBITDA of US$(5.7) million
      • Cash and other short-term assets[1] of US$224.1 million as of March 31, 2023

      Recent Business Updates

      • Joel Neoh, highly successful serial entrepreneur, joins Prenetics as Chief Consumer Officer and Managing Director for CircleDNA.
      • CircleDNA is poised to transform into a full-scale preventive and personalized healthcare management platform. This will involve expanding its portfolio to include a comprehensive suite of products and services, such as blood tests, telehealth services, bespoke supplements, and prescription drug deliveries, with launch by the fourth quarter of 2023.
      • ACT Genomics is set to launch a liquid biopsy version of its comprehensive genomic profiling test by the fourth quarter of 2023. Together, with the FDA-cleared ACTOnco product, this new product will be highly complementary and will allow ACT Genomics to offer both a tissue and a liquid test for solid tumors.

      Danny Yeung, Chief Executive Officer and Co-founder of Prenetics, said "2023 is a year of evolution for Prenetics as we execute our consumer health and clinical testing business strategy. Guided by our R&D team and Scientific Advisory Board, we are preparing for exciting product launches within CircleDNA and ACT Genomics by year-end. These innovations are projected to significantly bolster our fiscal health, enriching both our top and bottom lines. In order to bolster the strategic advancement in consumer health, we are thrilled to add Joel to our executive leadership team. Joel and I have known each other for more than 12 years and have been colleagues since both of our previous companies were acquired by Groupon in 2010. Joel's proven track record as a successful serial entrepreneur and his deep consumer insights underscore our commitment to growing CircleDNA into a leading global consumer health business. I'm confident with Joel at the helm, significant growth lies ahead for CircleDNA. We also believe our vast efforts in consumer health will play a highly synergistic role in our early cancer detection initiatives, in which we are immensely excited about and will share more in due course."

      Joel said "My entrepreneurial journey to date has been immensely rewarding, driven by my passion for making a difference. After spending the past 15 years building various global consumer platforms, I feel compelled to give back to the community by positively influencing people's health and showcasing the importance of prevention and health. I'm excited to join Danny and the exceptional team at Prenetics to spearhead the consumer health business. Leveraging our existing base of over 300,000 CircleDNA customers, I believe we can continue to grow and make a difference in millions of lives globally. By working with the best global scientists, doctors and clinicians, we intend to offer a suite of preventive and personalized healthcare solutions to empower people to live longer, happier and healthier lives."

      Joel Neoh Biography
      Joel Neoh is a serial entrepreneur and technology executive with over 15 years of top-flight leadership and board experience. Joel's experience in consumer technology spans sectors such as fintech, e-commerce, digital media, and health & wellness. Most recently, Joel was the founder of Fave, a leading Southeast Asian fintech platform backed by Sequoia Capital and acquired by Pine Labs, a unicorn company. Joel has been instrumental in accelerating digital payments and financial services for millions of consumers and merchants. Previously, Joel was the founder of GroupsMore, which was acquired by Groupon. While at Groupon, Joel headed up its Asia Pacific business, overseeing more than 2,000 employees. Joel's entrepreneurial journey started out by co-founding Says.com, one of Malaysia's largest digital news platforms. Joel is also a Board Director for the Institute of Corporate Directors Malaysia, promoting excellence in corporate governance. His entrepreneurial success and leadership led to his recognition as Ernst & Young Emerging Entrepreneur of the Year (Malaysia) in 2012, and as a Young Global Leader by the World Economic Forum in 2013.

      About Prenetics
      Prenetics is a leading genomics and precision oncology company dedicated to transforming patient care through advanced genomic and molecular technologies. Our mission is to revolutionize healthcare by integrating consumer health and genetics, breakthrough technology for early cancer detection, targeted treatments and genetic risk identification onto one comprehensive platform. We acquired ACT Genomics last December, the only Asia-based company to receive FDA clearance for a comprehensive genomics profiling test for solid tumors, enabling us to expand our capabilities and offer comprehensive cancer solutions to patients worldwide. Prenetics is listed on NASDAQ with the ticker PRE. To learn more about Prenetics, please visit www.prenetics.com.

      Forward-Looking Statements
      This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company's goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, objectives of management for future operations of the Company, and growth opportunities are forward-looking statements. In some cases, forward-looking statements can be identified by words or phrases such as "may," "will," "expect," "anticipate," "target," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to", "poised to", "set to" or other similar expressions. Forward-looking statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties, therefore they should not be relied upon as being necessarily indicative of future results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to: the Company's ability to further develop and grow its business, including new products and services; its ability to execute on its new business strategy in genomics, precision oncology, and specifically, early detection for cancer; and its ability to identify and execute on M&A opportunities, especially in precision oncology. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties described in the "Risk Factors" section of the Company's most recent registration statement on Form F-1 and the prospectus therein, and the other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

      Basis of Presentation
      Unaudited Financial Information and Non-IFRS Financial Measures has been provided in the financial statements tables included at the end of this press release. An explanation of these measures is also included below under the heading "Unaudited Financial Information and Non-IFRS Financial Measures."

      Unaudited Financial Information and Non-IFRS Financial Measures
      To supplement Prenetics' consolidated financial statements prepared in accordance with International Financial Reporting Standards ("IFRS"), the Company is providing non-IFRS measures, adjusted EBITDA, adjusted gross profit and adjusted (loss)/profit attributable to equity shareholders of Prenetics. These non-IFRS financial measures are not based on any standardized methodology prescribed by IFRS and are not necessarily comparable to similarly-titled measures presented by other companies. Management believes these non-IFRS financial measures are useful to investors in evaluating the Company's ongoing operating results and trends.

      Management is excluding from some or all of its non-IFRS results (1) Employee equity-settled share-based payment expenses, (2) depreciation and amortization, (3) finance income and exchange gain or loss, net, and (4) certain items that may not be indicative of our business, results of operations, or outlook, including but not limited to non-cash and/or non-recurring items. These non-IFRS financial measures are limited in value because they exclude certain items that may have a material impact on the reported financial results. Management accounts for this limitation by analyzing results on an IFRS basis as well as a non-IFRS basis and also by providing IFRS measures in the Company's public disclosures.

      In addition, other companies, including companies in the same industry, may not use the same non-IFRS measures or may calculate these metrics in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-IFRS measures as comparative measures. Because of these limitations, the Company's non-IFRS financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with IFRS. Investors are encouraged to review the non-IFRS reconciliations provided in the tables captioned "Reconciliation of (loss)/profit from operations under IFRS and adjusted EBITDA (Non-IFRS)", "Reconciliation of gross profit under IFRS and adjusted gross profit (Non-IFRS)" and "Reconciliation of (loss)/profit attributable to equity shareholders of Prenetics under IFRS and adjusted (loss)/profit attributable to equity shareholders of Prenetics (Non-IFRS)" set forth at the end of this document.

      PRENETICS GLOBAL LIMITED

      Unaudited consolidated statements of financial position

      (Expressed in United States dollars unless otherwise indicated)






      March 31,


      December 31,


      2023


      2022


      $


      $

      Assets




      Property, plant and equipment

      11,809,757


      13,102,546

      Intangible assets

      14,463,400


      14,785,875

      Goodwill

      33,800,276


      33,800,276

      Interests in associates

      677,339


      788,472

      Deferred tax assets

      7,626


      243,449

      Deferred expenses

      5,119,170


      6,307,834

      Other non-current assets

      1,064,194


      1,292,462

      Non-current assets

      66,941,762


      70,320,914





      Deferred expenses

      4,547,611


      4,577,255

      Inventories

      3,420,013


      4,534,072

      Trade receivables

      5,718,516


      41,691,913

      Deposits, prepayments and other receivables

      6,488,436


      6,889,114

      Amount due from an associate

      181,942


      -

      Financial assets at fair value through profit or loss

      17,537,608


      17,537,608

      Short-term deposits

      19,872,581


      19,920,160

      Cash and cash equivalents

      166,335,875


      146,660,195

      Current assets

      224,102,582


      241,810,317

      Total assets

      291,044,344


      312,131,231





      Liabilities




      Deferred tax liabilities

      2,924,369


      3,185,440

      Warrant liabilities

      2,314,609


      3,574,885

      Lease liabilities

      3,627,663


      3,763,230

      Other non-current liabilities

      830,562


      949,701

      Non-current liabilities

      9,697,203


      11,473,256





      Trade payables

      7,505,724


      7,291,133

      Accrued expenses and other current liabilities

      6,460,445


      15,611,421

      Contract liabilities

      4,917,268


      5,674,290

      Lease liabilities

      2,779,426


      2,882,933

      Liabilities for puttable financial instrument[2]

      17,459,600


      17,138,905

      Tax payable

      8,692,193


      8,596,433

      Current liabilities

      47,814,656


      57,195,115

      Total liabilities

      57,511,859


      68,668,371





      Equity




      Share capital[3]

      15,882


      13,698

      Reserves

      228,232,194


      237,050,429

      Total equity attributable to equity shareholders of the Company

      228,248,076


      237,064,127

      Non-controlling interests

      5,284,409


      6,398,733

      Total equity

      233,532,485


      243,462,860

      Total equity and liabilities

      291,044,344


      312,131,231

      PRENETICS GLOBAL LIMITED

      Unaudited consolidated statements of profit or loss and other comprehensive income

      (Expressed in United States dollars unless otherwise indicated)








      For the three months ended


      March 31,


      December 31,


      March 31,


      2023


      2022


      2022


      $


      $


      $







      Revenue

      17,700,142


      52,320,754


      92,044,049

      Direct costs

      (9,818,719)


      (25,317,570)


      (56,006,216)

      Gross profit

      7,881,423


      27,003,184


      36,037,833

      Other income and other net gain/(losses)

      1,223,124


      1,149,335


      (29,011)

      Selling and distribution expenses[4]

      (2,642,552)


      (2,503,384)


      (5,283,146)

      Research and development expenses[4]

      (3,474,554)


      (3,605,801)


      (3,821,490)

      Restructuring costs in relation to diagnostic business[5]

      -


      (2,709,143)


      -

      Administrative and other operating expenses[4]

      (15,032,140)


      (14,704,261)


      (27,454,847)

      (Loss)/profit from operations

      (12,044,699)


      4,629,930


      (550,661)

      Fair value loss on financial assets at fair value through profit or loss

      -


      (7,689,311)


      -

      Fair value loss on preference shares liabilities

      -


      -


      (28,276,001)

      Fair value gain on warrant liabilities

      1,260,276


      6,498,365


      -

      Share of losses of associates

      (112,751)


      -


      -

      Other finance costs

      (79,189)


      (116,029)


      (2,491,796)

      (Loss)/profit before taxation

      (10,976,363)


      3,322,955


      (31,318,458)

      Income tax credit/(expense)

      2,623


      (1,715,012)


      (1,667,438)

      (Loss)/profit for the period

      (10,973,740)


      1,607,943


      (32,985,896)







      Other comprehensive income for the period






      Item that may be reclassified subsequently to profit or loss:






        Exchange difference on translation of:






        - financial statements of subsidiaries outside Hong Kong

      (636,502)


      2,759,672


      (530,738)

      Total comprehensive income for the period

      (11,610,242)


      4,367,615


      (33,516,634)







      PRENETICS GLOBAL LIMITED

      Unaudited consolidated statements of profit or loss and other comprehensive income

      (Expressed in United States dollars unless otherwise indicated)








      For the three months ended


      March 31,


      December 31,


      March 31,


      2023


      2022


      2022


      $


      $


      $







      (Loss)/profit attributable to:






      Equity shareholders of Prenetics

      (10,398,430)


      1,607,942


      (32,985,850)

      Non-controlling interests

      (575,310)


      1


      (46)


      (10,973,740)


      1,607,943


      (32,985,896)







      Total comprehensive income attributable to:






      Equity shareholders of Prenetics

      (10,495,918)


      4,367,614


      (33,516,588)

      Non-controlling interests

      (1,114,324)


      1


      (46)


      (11,610,242)


      4,367,615


      (33,516,634)







      (Loss)/earnings per share:






      Basic

      (0.07)


      0.01


      (1.06)

      Diluted

      (0.07)


      0.01


      (1.06)







      Weighted average number of common shares:






      Basic

      157,839,309


      115,386,543


      31,207,949

      Diluted

      157,839,309


      162,708,402


      31,207,949

      PRENETICS GLOBAL LIMITED

      Unaudited Financial Information and Non-IFRS Financial Measures

      (Expressed in United States dollars unless otherwise indicated)







      Reconciliation of (loss)/profit from operations under IFRS and adjusted EBITDA (Non-IFRS)








      For the three months ended


      March 31,


      December 31,


      March 31,


      2023


      2022


      2022


      $


      $


      $







      (Loss)/profit from operations under IFRS

      (12,044,699)


      4,629,930


      (550,661)

      Employee equity-settled share-based payment expenses

      3,124,189


      3,241,872


      9,377,115

      Depreciation and amortization

      2,137,814


      1,333,231


      2,155,295

      Restructuring costs in relation to diagnostic business

      -


      2,709,143


      -

      Other strategic financing, transactional expense and non-recurring

        expenses

      2,238,906


      957,150


      1,695,185

      Finance income, exchange gain or loss, net

      (1,146,164)


      (751,171)


      31,772

      Adjusted EBITDA (Non-IFRS)

      (5,689,954)


      12,120,155


      12,708,706







      Reconciliation of gross profit under IFRS and adjusted gross profit (Non-IFRS)








      For the three months ended


      March 31,


      December 31,


      March 31,


      2023


      2022


      2022


      $


      $


      $







      Gross profit under IFRS

      7,881,423


      27,003,184


      36,037,833

      Depreciation and amortization

      384,326


      527,722


      417,619

      Adjusted gross profit (Non-IFRS)

      8,265,749


      27,530,906


      36,455,452







      Reconciliation of (loss)/profit attributable to equity shareholders of Prenetics under IFRS and adjusted (loss)/profit attributable to equity shareholders of Prenetics (Non-IFRS)








      For the three months ended


      March 31,


      December 31,


      March 31,


      2023


      2022


      2022


      $


      $


      $







      (Loss)/profit attributable to equity shareholders of Prenetics

        under IFRS

      (10,398,430)


      1,607,942


      (32,985,850)

      Employee equity-settled share-based payment expenses

      3,124,189


      3,241,872


      9,377,115

      Other strategic financing, transactional expense and non-recurring

        expenses

      2,238,906


      957,150


      1,695,185

      Fair value loss on preference shares liabilities

      -


      -


      28,276,001

      Fair value gain on warrant liabilities

      (1,260,276)


      (6,498,365)


      -

      Fair value loss on financial assets at fair value through profit or loss

      -


      7,689,311


      -

      Restructuring costs in relation to diagnostic business

      -


      2,709,143


      -

      Adjusted (loss)/profit attributable to equity shareholders of

        Prenetics (Non-IFRS)

      (6,295,611)


      9,707,053


      6,362,451

      [1] Represents current assets, including cash and cash equivalents and short-term deposits totaling US$186.2 million, financial assets at fair value through profit or loss of US$17.5 million, and trade receivables of US$5.7 million, amongst other accounting line items under current assets.

      [2] In connection with the acquisition of ACT Genomics, the remaining shareholders of ACT Genomics - representing 25.61% of the fully diluted shareholding of ACT Genomics that Prenetics does not own - were granted put options which allow these remaining shareholders to put their remaining shares to Prenetics under certain conditions. The liabilities arising from such put option are recorded as liabilities for puttable financial instrument, and are valued at the present value of the exercise price of the put option.

      [3] Represents number of authorized and issued shares as follows:


      March 31,


      December 31,


      2023


      2022





      Number of authorized shares of $0.0001 each

      500,000,000


      500,000,000





      Number of issued shares

      158,820,280


      136,983,110

      [4] Includes equity-settled share-based payment expenses (excluding share-based payment on listing) as follows:


      For the three months ended


      March 31,


      December 31,


      March 31,


      2023


      2022


      2022


      $


      $


      $







      Selling and distribution expenses

      45,255


      63,033


      9,492

      Research and development expenses

      486,507


      747,059


      1,249,618

      Administrative and other operating expenses

      2,574,249


      2,392,105


      7,896,731

      Total equity-settled share-based payment expenses (excluding

        share-based payment on listing)

      3,106,011


      3,202,197


      9,155,841

      [5] Includes restructuring costs in relation to diagnostic business as follows:


      For the three months ended


      March 31,


      December 31,


      March 31,


      2023


      2022


      2022


      $


      $


      $







      Impairment losses on property, plant and equipment

      -


      2,709,143


      -

      SOURCE Prenetics

      Modal title

      Contact PR Newswire

      • General Inquiries
      • Request a Demo
      • Partnerships
      • Media Inquiries

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Become a Publishing Partner
      • Careers
      • Accessibility Statement
      • APAC – Simplified Chinese
      • APAC
      • APAC - Traditional Chinese
      • Arabic
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • United States
      • Vietnam

      My Services

      • All New Releases
      • Platform

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact Cision

      Products

      About

      My Services
      • All News Releases
      • Platform
      [email protected]
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      • Accessibility
      Copyright © 2026 Cision US Inc.